WebPAOLA-1/ENGOT-ov25 ([NCT02477644][1]) is the first Phase III trial to evaluate the efficacy and safety of a PARP inhibitor with bevacizumab as first-line maintenance therapy, and in patients regardless of BRCA m status. Methodology PAOLA-1 is a randomized, double-blind, international Phase III trial. WebPAOLA-1/ENGOT-ov25 ([NCT02477644][1]) is the first Phase III trial to evaluate the efficacy and safety of a PARP inhibitor with bevacizumab as first-line maintenance therapy, and …

Annals of Oncology abstracts GYNAECOLOGICAL …

WebSep 28, 2024 · AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced detailed positive results from the Phase 3 PAOLA-1 trial showing LYNPARZA added to bevacizumab demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) in women with … WebNov 21, 2024 · Findings from a subgroup analysis of the phase III PAOLA-1/ENGOT-ov25 study presented at the ESMO Asia Virtual Congress 2024, held from 20 to 22 November … aiello gilda

Adding Olaparib to Bevacizumab Maintenance Improves …

Webthe phase 3 PAOLA-1 (PAOLA-1/ENGOT-ov25) trial, we evaluated maintenance therapy with a ... overall survival, the time until the first subsequent therapy or death, and the … WebMar 1, 2024 · A recent analysis of long-term overall survival (OS) at 7 years in the SOLO-1 phase III trial NCT01844986) confirmed the benefit of first-line maintenance olaparib ... with data maturity of 38.1%. In the PAOLA-1 phase III trial NCT02477644), no significant benefit in OS was observed with the addition of olaparib to bevacizumab compared to ... WebIn the PAOLA-1/ENGOT-ov25 (NCT02477644) primary analysis, adding ola to maintenance bev after first-line (1L) platinum-based chemotherapy (PBC) + bev led to a significant … aiello girolamo carini